Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PBYI Puma Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: PBYI
Price (delayed)
$3.07
Market cap
$152.31M
P/E Ratio
4.95
Dividend/share
N/A
EPS
$0.62
Enterprise value
$157.17M
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights
Highlights
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
The P/E is 55% lower than the last 4 quarters average of 10.9
Puma Biotechnology's quick ratio has decreased by 4.8% YoY
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
Key stats
What are the main financial stats of PBYI
Market
Valuations
Earnings
Shares outstanding
49.61M
Market cap
$152.31M
Enterprise value
$157.17M
Price to earnings (P/E)
4.95
Price to book (P/B)
1.64
Price to sales (P/S)
0.65
EV/EBIT
4.3
EV/EBITDA
3.27
EV/Sales
0.68
Revenue
$230.47M
Gross profit
$166.06M
Operating income
$30.97M
Net income
$30.28M
EBIT
$36.55M
EBITDA
$48.08M
Free cash flow
$38.86M
Per share
Balance sheet
Liquidity
EPS
$0.62
EPS diluted
$0.62
Free cash flow per share
$0.8
Book value per share
$1.88
Revenue per share
$4.74
TBVPS
$3.33
Total assets
$213.33M
Total liabilities
$121.21M
Debt
$74.08M
Equity
$92.13M
Working capital
$51.55M
Debt to equity
0.8
Current ratio
1.54
Quick ratio
1.38
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
20.9%
Gross margin
72.1%
Net margin
13.1%
Operating margin
13.4%
Return on assets
14.2%
Return on equity
46.1%
Return on invested capital
46.5%
Return on capital employed
31.2%
Return on sales
15.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PBYI stock price
How has the Puma Biotechnology stock price performed over time
Intraday
2.68%
1 week
-0.32%
1 month
6.23%
1 year
-36.44%
YTD
0.66%
QTD
3.72%
Financial performance
How have Puma Biotechnology's revenue and profit performed over time
Revenue
$230.47M
Gross profit
$166.06M
Operating income
$30.97M
Net income
$30.28M
Gross margin
72.1%
Net margin
13.1%
Puma Biotechnology's net margin has increased by 42% YoY and by 38% QoQ
The net income has grown by 40% YoY and by 30% from the previous quarter
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
The operating income has contracted by 5% YoY and by 4.4% from the previous quarter
Price vs fundamentals
How does PBYI's price correlate with its fundamentals
Growth
What is Puma Biotechnology's growth rate over time
Valuation
What is Puma Biotechnology stock price valuation
P/E
4.95
P/B
1.64
P/S
0.65
EV/EBIT
4.3
EV/EBITDA
3.27
EV/Sales
0.68
The P/E is 55% lower than the last 4 quarters average of 10.9
PBYI's EPS is up by 35% year-on-year and by 29% since the previous quarter
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
PBYI's P/B is 43% lower than its last 4 quarters average of 2.9
PBYI's P/S is 35% below its 5-year quarterly average of 1.0 and 19% below its last 4 quarters average of 0.8
The revenue has contracted by 5% from the previous quarter and by 2.2% YoY
Efficiency
How efficient is Puma Biotechnology business performance
PBYI's ROIC is up by 49% YoY and by 4.7% QoQ
The ROA has increased by 37% YoY and by 33% QoQ
Puma Biotechnology's ROE has decreased by 21% YoY but it has increased by 11% from the previous quarter
PBYI's return on sales is up by 3.9% year-on-year and by 2.6% since the previous quarter
Dividends
What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PBYI.
Financial health
How did Puma Biotechnology financials performed over time
The total assets is 76% more than the total liabilities
The total liabilities has contracted by 32% YoY and by 19% from the previous quarter
The company's current ratio rose by 8% QoQ
Puma Biotechnology's debt is 20% lower than its equity
Puma Biotechnology's equity has surged by 72% YoY and by 30% QoQ
Puma Biotechnology's debt to equity has shrunk by 62% YoY and by 34% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.